BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

With U.S. stocks booming, North American wealthy led the way globally. And the top 1% of wealthy globally—the so-called ...